Awards Ceremony
On the afternoon of December 28, 2023, the 6th Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Innovation Enterprise Top 50 Awards Ceremony was grandly held in Nansha, Guangzhou. Hosted by China Creation Industry Research Institute and organized by Guangdong Medical Valley, this annual event has been successfully held for six consecutive years, attracting widespread attention and coverage from government departments, scholars and experts, media, and biotechnology enterprises.
This year's selection, Guangzhou Raytec Biotechnology Co., Ltd. stood out for its remarkable performance in technological innovation, product advantages, industrialization capabilities, talent team, industry status, and social responsibility. The company was honored to be listed in the Top 50 Biotechnology Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area for the sixth consecutive year and was awarded the titles of "Pioneer Enterprise" and "Most Investment-worthy Enterprise of 2023".
Enterprise achievements
As a high-tech enterprise specializing in the research and development, production, and sales of recycled repair materials and related medical device products, Raytec Biotechnology has always adhered to technological innovation and continuously promoted industrial upgrading since its establishment in 2014. In April 2020, the company independently developed the first active wet state biological amniotic membrane "Ruixiu Fu®”in China Officially launched, it was rated as a "Guangdong Province Famous High tech Product (the first domestically replaceable imported product)" that year. This product uses a safe and efficient processing technology combined with an exclusively developed amniotic membrane preservation solution to create a biological amniotic membrane with activity similar to fresh amniotic membrane and superior product characteristics to fresh amniotic membrane, with a shelf life of up to 3 years. At present, 26 provinces have completed network deployment, achieving full coverage of 500 tertiary hospitals in China, as well as listed ophthalmic hospitals such as Aier, Huaxia, and He's.
On June 20th, 2023, the first scleral lens in China, "Epicon A®" introduced by Raytec Biotechnology, was approved for marketing. Within five months of its launch, it has successfully been fitted with over 1,000 lenses. This product, along with the globally unique scleral lens care device "Epjing TM" approved by the US FDA and launched by the company at the same time, forms a complete solution for the entire usage cycle of scleral lens fitting, cleaning, and disinfection.
Honors Received
Being listed as one of the Top 50 Biotechnology Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area for the sixth consecutive year and receiving the two awards of "Pioneer Enterprise" and "Most Investment-worthy Enterprise of 2023" are great honors for Raytec Biotechnology. This not only affirms the achievements made by Raytec Biotechnology in areas such as technological innovation, product research and development, and industrialization in the past few years, but also holds great expectations for its future development.
Favorite in Capital Markets
It is worth mentioning that apart from its advantages in technological innovation, Raytec Biotechnology has also attracted considerable attention in the capital markets. In the 2023 Guangzhou Pre-IPO Companies "Leading Sheep" Award list, which was previously announced and supported by the Guangzhou Local Financial Supervisory Administration and organized by the Guangzhou Financial Development Service Center in conjunction with the Industrial and Commercial Bank of China Guangzhou Branch, Guangdong Equity Exchange, GF Securities, and Guangzhou venture capital institutions, Raytec Biotechnology was prominently listed. This honor not only demonstrates Raytec Biotechnology's excellent performance and huge potential in the capital markets, but also injects strong momentum into the company's future development.
2023 Guangzhou Pre-IPO Companies "Leading Sheep" Top 50 List (Ranked by Number of Strokes)
A Long Way to Go with Heavy Responsibilities
Both the honorable titles earned in the field of technological innovation and the impressive achievements in the capital markets, Raytec Biotechnology states that they will cherish these opportunities and use them as a springboard to continue adhering to the corporate spirit of "cooperation and win-win," as well as the development philosophy of "technological innovation, talent as the foundation, responsibility as the utmost priority"，we will continue to improve product quality, expand market share, and strive diligently to achieve the company's long-term development goals.
Looking to the future, we believe that Raytec Biotechnology will continue to achieve more glorious accomplishments in the field of biotechnology and make greater contributions to the development of human health.